Expression of Matrix Metalloproteinase-9 in Head and Neck Squamous Cell Carcinoma: A Potential Marker for Prognosis

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3110-3116

  Ruokolainen, Henni ^a   Pääkkö, Paavo ^a   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; GELATINASE B; MONOCLONAL ANTIBODY; STREPTAVIDIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SEX FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 2442428314     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0530     Document Type: Article

References (38)

1. Vokes EE, Weichselbaum RR, Lippman SM, Ki Hong W. Head and neck cancer. N Engl J Med 1993;328:184-94.
2. Pivot X, Niyikiza C, Poissonnet G, et al. Clinical prognostic factors for patients with recurrent head and neck cancer: Implications for randomized trials. Oncology 2001;61:197-204.
3. Poole ME, Sailer SL, Rosenman JG, et al. Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation. Arch Otolaryngol Head Neck Surg 2001; 127:1446-50.
4. Cerezo L, Millan I, Torre A. Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate study of 492 cases. Cancer (Phila.) 1992;69: 1224-34.
5. Leemans CR, Tiwari R, Nauta JJ. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer (Phila.) 1994;73:187-90.
6. Mamelle G, Pampurik J, Luboinski B. Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg 1994;168: 494-8.
7. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
8. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990;1:99-106.
9. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
10. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10:602-8.
11. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990;9:289-303.
12. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-54.
13. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11:143-52.
14. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7: 14-23.
15. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Investig (Lond.) 1999;103:1237-41.
16. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 2001;10:383-92.
17. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998;186:51-8.
18. Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein-a new prognostic marker in uveal melanoma? J Pathol 1999;188:56-62.
19. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer (Phila.) 1998;83:1153-62.
20. Sienel W, Hellers J, Morresi-Hauf A, et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003;103:647-51.
21. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7: 3113-9.
22. Charous SJ, Stricklin GP, Nanney LB, Netterville JL, Burkey BB. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 1997;106:271-8.
23. Kawamata H, Uchida D, Hamano H, et al. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol 1998;13:699-704.
24. Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinase and oral cancer. Oral Oncology 1999;35:227-33.
25. Ikebe T, Shinohara M, Takeuchi H, et al. Gelatinolytic activity of matrix metallproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis 1999;17:315-23.
26. Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999;21: 627-38.
27. Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995; 104:678-84.
28. International Union Against Cancer. TNM classification of malignant tumors. Geneva, Switzerland. Wiley-Liss, 1997.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
30. Riedel F, Gotte K, Schwalb J, Hormann K. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Res 2000;20:3045-9.
31. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol 2000;36:207-13.
32. Yorioka CW, Coletta RD, Alves F, Nishimoto IN, Kowalski LP, Graner E. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol 2002;20:189-94.
33. Ondruschka C, Buhtz P, Motsch C, et al. Prognostic value of MMP-2, -9 and TIMP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract 2002;198:509-15.
34. Nathan CA, Amirghahri N, Rice C, Abreo FW, Shi R, Stucker FJ. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope 2002;112:2129-40.
35. Ranuncolo SM, Matos E, Loria D, et al. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer (Phila.) 2002;94:1483-91.
36. Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000;17:1099-105.
37. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer (Phila.) 2002;95:1902-10.
38. Scorilas A, Karameris A, Arnogiannaki N, et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001;84:1488-96.